Scalper1 News
Big biotech Celgene (CELG) beat analysts’ Q3 earnings expectations but came up short on the top line Thursday morning, sending shares down sharply in early trading. Celgene earnings rose 27% over the year-earlier quarter to $1.23 a share, excluding one-time items, beating analysts’ consensus by a penny. Revenue climbed 18% to $2.33 billion, about $70 million below consensus, according to Thomson Reuters. Celgene affirmed its previous full-year Scalper1 News
Scalper1 News